Selective estrogen receptor modulators in reproductive medicine and biology

被引:34
作者
Baker, VL
Leitman, D
Jaffe, RB [1 ]
机构
[1] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Ctr Reprod Endocrinol, San Francisco, CA 94143 USA
[2] Univ Washington, Dept Obstet & Gynecol, Div Reprod Endocrinol, Seattle, WA 98195 USA
关键词
D O I
10.1097/00006254-200007001-00001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Estrogen replacement therapy has significant potential benefits for postmenopausal women, such as improvement of menopausal symptoms and protection from osteoporosis, but it may also increase a woman's risk of breast cancer. Also, some women do not take hormone replacement therapy because of such undesirable side effects as breast tenderness and uterine bleeding. Therefore, there is much interest in the development of compounds that provide the benefits of estrogen replacement therapy without the risks and side effects. The selective estrogen receptor modulators make up one class of compounds with both estrogen agonist and antagonist activity. This review discusses the clinical indications, risks, benefits, and mechanisms of action of selective estrogen receptor modulators and related compounds.
引用
收藏
页码:S21 / S47
页数:27
相关论文
共 168 条
  • [11] Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys
    Anthony, MS
    Clarkson, TB
    Bullock, BC
    Wagner, JD
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2524 - 2531
  • [12] The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms
    Arjmandi, BH
    Birnbaum, RS
    Juma, S
    Barengolts, E
    Kukreja, SC
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2000, 66 (01) : 61 - 65
  • [13] Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis
    Arjmandi, BH
    Alekel, L
    Hollis, BW
    Amin, D
    StacewiczSapuntzakis, M
    Guo, P
    Kukreja, SC
    [J]. JOURNAL OF NUTRITION, 1996, 126 (01) : 161 - 167
  • [14] Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content
    Arjmandi, BH
    Birnbaum, R
    Goyal, NV
    Getlinger, MJ
    Juma, S
    Alekel, L
    Hasler, CM
    Drum, ML
    Hollis, BW
    Kukreja, SC
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (06) : 1364S - 1368S
  • [15] DIETARY INTERVENTION STUDY TO ASSESS ESTROGENICITY OF DIETARY SOY AMONG POSTMENOPAUSAL WOMEN
    BAIRD, DD
    UMBACH, DM
    LANSDELL, L
    HUGHES, CL
    SETCHELL, KDR
    WEINBERG, CR
    HANEY, AF
    WILCOX, AJ
    MCLACHLAN, JA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (05) : 1685 - 1690
  • [16] BAKER V, 1996, J CLIN ENDOCR METAB, V83, P6
  • [17] TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES
    BARAKAT, RR
    WONG, G
    CURTIN, JP
    VLAMIS, V
    HOSKINS, WJ
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 55 (02) : 164 - 168
  • [18] Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists
    Barkhem, T
    Carlsson, B
    Nilsson, Y
    Enmark, E
    Gustafsson, JÅ
    Nilsson, S
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (01) : 105 - 112
  • [19] Uterine side effects of tamoxifen:: A need for systematic pretreatment screening
    Berlière, M
    Charles, A
    Galant, C
    Donnez, J
    [J]. OBSTETRICS AND GYNECOLOGY, 1998, 91 (01) : 40 - 44
  • [20] Tamoxifen therapy for breast cancer and endometrial cancer risk
    Bernstein, L
    Deapen, D
    Cerhan, JR
    Schwartz, SM
    Liff, J
    McGann-Maloney, E
    Perlman, JA
    Ford, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) : 1654 - 1662